Several drugmakers, including Mylan and Lupin, are said to be considering bids for Bayer's dermatology unit, as the German drugmaker looks to divest in order to push forward its Monsanto acquisition, according to Bloomberg sources.
Denmark-based Leo Pharma, India-based Cadila Healthcare and India-based Torrent Pharmaceuticals are also said to be weighing offers.
Sources say non-binding bids for Bayer’s dermatology unit, which could bring in more than $1.1 billion, may be due as soon as this week.
Read the Bloomberg exclusive